A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Sponsor: FORMA Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS0654
U.S. Govt. ID: NCT03684811
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This clinical trial will investigate an experimental drug called FT-2102. FT-2102 targets tumor cells that have an abnormal gene (code that tells your body what proteins to make), called isocitrate dehydrogenase 1 (IDH1). Research subjects with either a Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic cholangiocarcinoma (IHCC), a Glioma, or another solid tumor may participate. The purpose of this study is to see if FT-2102 alone or combined with either azacitidine, nivolumab, or gemcitabine plus cisplatin (GemCis) is safe and tolerable.
This study is closed
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic cholangiocarcinoma (IHCC), a Glioma, or another solid Yes No
Does your cancer continue to grow despite treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE